SCHEMBL260746

SCHEMBL260746

CC1(C)O[C@@H]2[C@H](O1)[C@@H](C(=O)O)O[C@H]2n1cnc2c(N)nc(C#N)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.47
PI4K2B Q8TCG2 1/20 0.47
PI4K2A Q9BTU6 1/20 0.47
PI4KB Q9UBF8 1/20 0.47
ADORA2A P29274 5/20 0.47
ADORA3 P0DMS8 3/20 0.47
ADORA1 P30542 3/20 0.47
ADORA2B P29275 2/20 0.45
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
PMP22 Q01453 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
HIF1A Q16665 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260577 0.92 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL260716 0.90 ADORA3 (0.40) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL280519 0.88 ADORA2A (0.47) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL12935980 0.87 ADORA2A (0.60) ADORA2AADORA2BALDH1A1GLAPMP22
SCHEMBL260607 0.87 ADORA3 (0.55) ADORA2AADORA3ADORA1ADORA2B
SCHEMBL13296261 0.86 ADORA3 (0.50) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL13913203 0.86 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL326428 0.86 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL13433886 0.86 ADORA3 (0.50) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL13461113 0.86 ADORA3 (0.50) PI4KAPI4K2BPI4K2API4KBADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133880-B2 Purine derivatives and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2012-03-13 US disclosed
US-8133880-B2 Purine derivatives and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2012-03-13 US disclosed
EP-1802316-B1 PURINE DERIVATIVES AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORP (US) 2011-11-02 EP disclosed
US-20110059915-A1 PURINE DERIVATIVES AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2011-03-10 US disclosed
US-20110059915-A1 PURINE DERIVATIVES AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2011-03-10 US disclosed
US-7863253-B2 Purine Derivatives and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2011-01-04 US disclosed
US-7863253-B2 Purine Derivatives and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2011-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059915-A1 PURINE DERIVATIVES AND METHODS OF USE THEREOF PNP, NUDT1, HPRT1 PI4KA 1919/4885PI4K2B 2485/4885PI4K2A 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.